The primary research interests of Qian Shi, Ph.D., are in the area of the conduct and methodology of clinical trials in cancer. Dr. Shi works to develop innovative statistical study design to run more efficient clinical trials that deliver effective, novel treatments to cancer patients. Additional areas of active research include evaluation and methodology of surrogate endpoints, meta-analyses of individual patient data from a large collection of clinical trials, survival analysis, and prognostic and predictive biomarker analysis.
Dr. Shi is involved in multiple ongoing clinical trials of both therapeutic and surgical cancer treatment. She leads the Sargent Hypothesis Analysis in the Research of Endpoint (SHARE). This independent statistics and data center team supports meta-database integration and analysis projects for the following large international collaborations:
- Adjuvant Colon Cancer End Points (ACCENT) group
- Analysis and Research in Cancers of the Digestive System (ARCAD) group
- International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration
- Follicular Lymphoma Analysis of Surrogate Hypothesis (FLASH) group
- Surrogate Endpoint in Aggressive Lymphoma (SEAL) group
Significance to patient care
The research conducted by Dr. Shi contributes to an increased understanding of tumor genetics and patient factors that make disease more or less aggressive. When successful, the clinical trials that Dr. Shi participates in directly result in new treatment options for patients with cancer.
- Lead consulting statistician, Gastrointestinal Cancer Program, Mayo Clinic Cancer Center, 2016-present
- Lead statistician, Gastrointestinal Committee, Biostatistics unit of the Statistics and Data Management Program, Alliance for Clinical Trials in Oncology, 2016-present
- Associate Director for Statistics, Alliance Statistics and Data Center, Alliance for Clinical Trials in Oncology, 2015-present